Bendamustine is widely used in the treatment of hematological cancers such as chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin lymphoma (NHL), especially in patients who do not respond to first-line therapies like rituximab. It works by damaging the DNA of cancer cells, thereby inhibiting their growth and promoting cell death. Bendamustine can be administered alone or in combination with other chemotherapy drugs, making it effective in relapsed or refractory cases. It is commonly used in clinical oncology settings to slow disease progression, provide palliative care, and improve overall survival and quality of life in patients.
Image
